Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822768 | 0.77 | HTR2A (0.42) | HASPINCYP2C9CYP2C19NFATC1GSK3B | |
| SCHEMBL24669478 | 0.76 | USP2 (0.38) | HASPINCYP2C9CYP2C19NFATC1GSK3B | |
| SCHEMBL15935200 | 0.76 | HASPIN (0.37) | HASPINCYP2A6CYP2C9CYP2C19NFATC1 | |
| SCHEMBL24668531 | 0.73 | HASPIN (0.35) | HASPINCYP2A6CYP2C19GSK3BDYRK1A | |
| SCHEMBL152013 | 0.73 | CYP19A1 (0.45) | CYP2A6CYP2C9CYP2C19DYRK1AMAPT | |
| SCHEMBL5004695 | 0.71 | ALDH1A1 (0.36) | TOP2A | |
| SCHEMBL31613470 | 0.70 | PRKCZ (0.48) | HASPINCYP2A6CYP2C9CYP2C19DYRK1A | |
| Hydrochloric Acid SCHEMBL38666248 | 0.70 | CYP19A1 (0.43) | CYP2A6CYP2C9CYP2C19DYRK1AMAPT | |
| SCHEMBL140144 | 0.70 | PRKCZ (0.48) | HASPINCYP2A6CYP2C9CYP2C19DYRK1A | |
| Bromide SCHEMBL30097072 | 0.70 | CYP19A1 (0.43) | HASPINCYP2A6CYP2C9CYP2C19DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242511-A1 | FUSED PYRAZOLE AND IMIDAZOLE BASED COMPOUNDS AND USE THEREOF AS GLI1 INHIBITORS | GLIXOGEN THERAPEUTICS LTD. (IL) | 2023-08-03 | — | — | US | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022263548-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | LEAD DISCOVERY CENTER GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4104901-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | Lead Discovery Center GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| US-20210198269-A1 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-07-01 | — | — | US | disclosed |
| EP-2935247-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-3498701-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-2935243-B1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | EPIZYME INC (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| WO-2012041292-A2 | COMPOUNDS FOR DIAGNOSING NEURODEGENERATIVE DISEASES AT THE RETINA | KLINIKUM DARMSTADT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012037928-A2 | COMPOUNDS FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISORDERS ON THE OLFACTORY EPITHELIUM | KLINIKUM DARMSTADT GMBH (DE) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012028332-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-2423208-A1 | Pharmaceutically active compounds as Axl inhibitors | Lead Discovery Center GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-20120007063-A1 | USE OF DIBENZOFURANS AND DIBENZOTHIOPHENES SUBSTITUTED BY NITROGEN-BONDED FIVE-MEMBERED HETEROCYCLIC RINGS IN ORGANIC ELECTRONICS | BASF SE (DE) | 2012-01-12 | — | — | US | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-2210881-A1 | Derivatives of syringolin A | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081731-A2 | DERIVATIVES OF SYRINGOLIN A | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V (DE) | 2010-07-22 | — | — | WO | disclosed |
| WO-2008055488-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | TGM2, TGM3, TGM1 | HASPIN 3427/4885CYP2A6 4088/4885CYP2C9 2482/4885 |
| US-20120007063-A1 | USE OF DIBENZOFURANS AND DIBENZOTHIOPHENES SUBSTITUTED BY NITROGEN-BONDED FIVE-MEMBERED HETEROCYCLIC RINGS IN ORGANIC ELECTRONICS | DDT, DBF4, POU5F1 | HASPIN 4333/4885CYP2A6 2473/4885CYP2C9 575/4885 |
| US-20210198269-A1 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) | SLC2A1, SLC2A3, SLC2A4 | HASPIN 1794/4885CYP2A6 675/4885CYP2C9 623/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | HASPIN 1693/4885CYP2A6 3503/4885CYP2C9 2246/4885 |
| US-20230242511-A1 | FUSED PYRAZOLE AND IMIDAZOLE BASED COMPOUNDS AND USE THEREOF AS GLI1 INHIBITORS | GLI1, SHH, GLI2 | HASPIN 1459/4885CYP2A6 3656/4885CYP2C9 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.